These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37116986)

  • 1. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.
    Messelink MA; den Broeder AA; Marinelli FE; Michgels E; Verschueren P; Aletaha D; Tekstra J; Welsing PMJ
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37116986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
    Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
    Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients.
    Dhaon P; Das SK; Srivastava R; Dhakad U
    Int J Rheum Dis; 2018 Nov; 21(11):1933-1939. PubMed ID: 28608433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
    Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis.
    Janke K; Kiefer C; McGauran N; Richter B; Krause D; Wieseler B
    BMC Rheumatol; 2022 Dec; 6(1):82. PubMed ID: 36482451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt.
    Martins FM; da Silva JA; Santos MJ; Vieira-Sousa E; Duarte C; Santos H; Costa JA; Pimentel-Santos FM; Cunha I; Cunha Miranda L; Nóvoa T; Cruz M; Bernardes M; Araujo D; Pereira Silva JA; Silva JC; Branco JC; Gomes JA; Faustino A; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2015 Feb; 54(2):286-91. PubMed ID: 25173347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy.
    Hirano F; Yokoyama W; Yamazaki H; Amano K; Kawakami A; Hayashi T; Tamura N; Yasuda S; Dobashi H; Fujii T; Ito S; Kaneko Y; Matsui T; Okuda Y; Saito K; Suzuki F; Yoshimi R; Sakai R; Koike R; Kohsaka H; Miyasaka N; Harigai M;
    Mod Rheumatol; 2017 Sep; 27(5):811-819. PubMed ID: 27919205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.
    Gaujoux-Viala C; Mouterde G; Baillet A; Claudepierre P; Fautrel B; Le Loët X; Maillefert JF
    Joint Bone Spine; 2012 Mar; 79(2):149-55. PubMed ID: 21680221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
    Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis.
    Slama IB; Allali F; Lakhdar T; El Kabbaj S; Medrare L; Ngeuleu A; Rkain H; Hajjaj-Hassouni N
    BMC Musculoskelet Disord; 2015 Sep; 16():268. PubMed ID: 26420567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
    Schoels M; Alasti F; Smolen JS; Aletaha D
    Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis.
    Futó G; Somogyi A; Szekanecz Z
    Clin Rheumatol; 2014 May; 33(5):623-9. PubMed ID: 24599677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept.
    Bessette L; Haraoui B; Rampakakis E; Dembowy J; Trépanier MO; Pope J
    Arthritis Res Ther; 2023 Sep; 25(1):183. PubMed ID: 37759330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
    Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
    Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.